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Objectives Early identification of myocardial infarction in chest pain patients is crucial to identify patients at risk and to
maintain a fast treatment initiation.
Background The aim of the current investigation is to test whether determination of copeptin, an indirect marker for arginin-vasopressin,
adds diagnostic information to cardiac troponin in early evaluation of patients with suspected myocardial infarction.
Methods Between January 2007 and July 2008, patients with suspected acute coronary syndrome were consecutively
enrolled in this multicenter study. Copeptin, troponin T (TnT), myoglobin, and creatine kinase-myocardial band
were determined at admission and after 3 and 6 h.
Results Of 1,386 (66.4% male) enrolled patients, 299 (21.6%) had the discharge diagnosis of acute myocardial infarction,
184 (13.3%) presented with unstable angina, and in 903 (65.2%) an acute coronary syndrome could be excluded.
Combined measurement of copeptin and TnT on admission improved the c-statistic from 0.84 for TnT alone to 0.93
in the overall population and from 0.77 to 0.9 in patients presenting within 3 h after chest pain onset (CPO) (p 0.001). In
this group the combination of copeptin with a conventional TnT provided a negative predictive value of 92.4%.
Conclusions In triage of chest pain patients, determination of copeptin in addition to troponin improves diagnostic performance,
especially early after CPO. Combined determination of troponin and copeptin provides a remarkable negative predic-
tive value virtually independent of CPO time and therefore aids in early and safe rule-out of myocardial infarction.
(J Am Coll Cardiol 2010;55:2096–106) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.029fi
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sarly identification of myocardial infarction (MI) in chest
ain patients is crucial to maintain a fast treatment initia-
ion. Diagnosis of acute myocardial infarction (AMI) relies,
esides clinical symptoms and electrocardiographic (ECG)
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009, accepted January 2, 2010.ndings, primarily on biomarker levels. Markers of myocar-
ial necrosis such as cardiac troponin and creatine kinase-
yocardial band (CK-MB) are the gold standard in detec-
ion of AMI, and their use is recommended by current
uidelines (1). In particular, cardiac troponin provides
xcellent specificity (2,3).
The delayed release of necrosis markers after cell disin-
egration might explain the weakness in diagnostic perfor-
ance of conventional troponin assays early after chest pain
nset (CPO) (4). Therefore, markers with pathophysiologic
ackground independent of cell necrosis might improve
apid diagnosis of AMI.
The antidiuretic hormone arginin-vasopressin (AVP) is
ecreted neurohypophyseal and controls osmotic homeosta-
is (5). Release of AVP is regulated by hyperosmolality,
ypovolemia (6), hypotension, hypothalamic osmoreceptors
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May 11, 2010:2096–106 Copeptin in Diagnosis of Myocardial Infarctionnd angiotensin II, reflecting individual stress level (7). The
VP-induced vasoconstriction is mediated by the V1a
eceptor on smooth muscle cells, the antidiuretic effect by
he V2 receptor on the distal kidney tubule, and the IP3
ignal transduction pathway (8,9). Clinical relevance of
VP is given by its potential role in pathogenesis and its
iagnostic value in congestive heart failure (10) and remod-
ling after AMI (11). As endocrine stress response, the AVP
evels increase in shock and cardiac arrest (12–14). Routine
easurement of AVP in clinical practice is prevented by
arious reasons, such as short half-life time (15), platelet
inding (16), and assay variations. The glycosylated peptide
opeptin is part of the uncleaved pro-AVP and emerges
quimolar to AVP, because both are derived from the
recursor prepro-AVP along with neurophysin II; therefore,
t serves as an indirect marker for AVP. A recently devel-
ped assay for copeptin delivers the stability and reproduc-
bility direct measurement of AVP is lacking (17).
The release pattern of copeptin in patients with AMI
ith immediate rise after onset of chest pain and decrease
oward physiologic levels within 5 days (18) as well as the
otential use of copeptin in rule-out of AMI (19) was
escribed recently. Thus, the role of copeptin as diagnostic
arker in suspected acute coronary syndrome (ACS) needs
o be evaluated in large prospective cohorts.
The aim of the current investigation is to prospectively
est whether copeptin adds diagnostic information to that
rovided by troponin and whether the combination of
opeptin and troponin is superior to the combination of
yoglobin and troponin in early evaluation of patients with
uspected AMI.
ethods
tudy population. All patients with suspected ACS pre-
enting consecutively at the chest pain units of the Univer-
ity Medical Center of the Johannes Gutenberg-University
ainz, the Federal Armed Hospital Koblenz, or the Uni-
ersity Hospital Hamburg-Eppendorf between January
007 and July 2008 were enrolled in this study, to reflect an
nbiased real world population.
Patients older than 18 years and younger than 85 years of
ge with angina pectoris or equivalent symptoms were
ligible to participate. Exclusion criteria were trauma or
ajor surgery within the last 4 weeks, pregnancy, intrave-
ous drug abuse, and anemia (hemoglobin 10 g/dl).
Patients treated with antihypertensive drugs at enroll-
ent or who had previous diagnosis of hypertension were
lassified as hypertensive. Patients were categorized as
urrently smoking, former smoking (if stopped 4 weeks to
0 years prior), and nonsmoker (if stopped smoking 40
ears ago). Patients receiving dietary treatment or medica-
ion for diabetes were considered to have diabetes mellitus.
e considered patients with previously diagnosed hyperlip-
demia or with total cholesterol200 mg/dl at admission as
yperlipidemic. hBlood was drawn at admission
nd after 3 and 6 h. A 12-lead
CG was obtained at the same
ime points.
Diagnosis of AMI was estab-
ished according to the universal
efinition of MI (1). Patients
ith symptoms of myocardial
schemia together with ECG
hanges and/or elevated biomar-
ers of myocardial necrosis were
ategorized as having an AMI.
elevant ECG changes were de-
ned as follows: ST-segment el-
vation 0.2 mV in at least 2
ontiguous leads in V2 to V6 or
T-segment elevation 0.1 mV
n other leads or with new left
undle branch block documented
n ECG at admission or in out-
atient clinic ECG were classi-
ed as AMI with ST-segment
levation; and ST-segment de-
ression and T- or Q-wave
hanges were classified as ECG
igns representative for acute
schemia. Necrosis of myocar-
ium was noted if at least 1
etermination of in-house tropo-
in exceeded the predefined up-
er reference limit of the corre-
ponding assay and if a typical
inetic with rise or fall 20%
ithin 6 h after admission could be observed.
Unstable angina pectoris (UAP) was diagnosed if ECG
as nondiagnostic; in-house troponin was negative, but
oronary angiography revealed a culprit lesion; or ischemia
as proven in stress test with subsequent need of coronary
ntervention. All patients with excluded ACS were catego-
ized as having noncoronary chest pain (NCCP). Final
iagnosis was made by an expert committee of 2 cardiolo-
ists, blinded to copeptin values, on the basis of all available
linical, laboratory, and imaging findings.
The study was approved by the local ethics committees in
heinland-Pfalz and Hamburg. Participation was volun-
ary; each patient gave written, informed consent.
lood sampling and laboratory methods. Routine labo-
atory parameters, including C-reactive protein, creatinine,
yoglobin, N-terminal pro-brain natriuretic peptide (NT-
roBNP), and CK-MB, were measured immediately after
lood withdrawal by standardized methods. Additionally,
thylenediaminetetraacetic acid plasma, citrate plasma, and
erum samples were collected at each time point, centri-
uged, and frozen at 80°C.
Cardiac troponin T (TnT) (Roche Diagnostics, Mann-
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
AMI  acute myocardial
infarction
AUC  area under the
curve
AVP  arginin-vasopressin
CK-MB  creatine kinase-
myocardial band
CPO  chest pain onset
CV  coefficient of
variation
ECG  electrocardiogram/
electrocardiographic
MI  myocardial infarction
NCCP  noncoronary chest
pain
NPV  negative predictive
value
NT-proBNP  N-terminal
pro-brain natriuretic peptide
PPV  positive predictive
value
ROC  receiver operating
characteristic
TnI  troponin I
TnT  troponin T
UAP  unstable angina
pectoriseim, Germany) representing in-house troponin at 2 study
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Copeptin in Diagnosis of Myocardial Infarction May 11, 2010:2096–106enters was measured at each time point in all patients with
he electrochemiluminescence immunoassay (ECLIA)
echnology on an Elecsys 2010 system with detection limit
f 0.01 ng/ml and measuring range of 0.01 to 25 ng/ml.
eference limit based on the 99th percentile for a healthy
opulation was 0.01 ng/ml, and 10% coefficient of variation
CV) was 0.03 ng/ml, which was used as diagnostic cutoff.
n-house cardiac troponin I (Dimension RxL TnI, Siemens
ealthcare Diagnostics, Erlangen, Germany) was used at 1
tudy center for adjudication of final diagnosis. The assay
ad a detection limit of 0.04 ng/ml with a measuring range
f 0.04 to 40 ng/ml. The 99th percentile was 0.07 ng/ml,
nd the 10% CV used as diagnostic cutoff was 0.14 ng/ml.
dditionally, sensitive cardiac troponin I with the TnI-
ltra assay (Siemens Healthcare Diagnostics) was deter-
ined on an ADVIA Centaur XP system. The assay
etection limit was 0.006 ng/ml, measuring range was 0.006
aseline Characteristics of 1,386 Patients With Chest PainTable 1 Baseline Characteristics of 1,386 Patients With Chest
NCCP
n 903 (65.2)
Age (yrs) 59.8 14.3
Male sex 569 (63)
Traditional risk factors
Body mass index (kg/m2) 27.8 5
Waist/hip ratio 0.98 (0.93/1.03) 0
Hypertension 640 (70.9)
Diabetes mellitus 135 (15.1)
Smoking status
Current smoker 192 (21.4)
Former smoker 263 (31.1)
Never smoked 437 (49.3)
Hyperlipidemia 624 (69.1)
Lipid status
Total cholesterol (mg/dl) 194.1 45
HDL cholesterol (mg/dl) 52.7 16.3
LDL cholesterol (mg/dl) 113.6 38.9
LDL/HDL ratio 2.2 (1.6/2.8)
Parental CAD 302 (34.5)
Known CAD 285 (32.6)
Laboratory parameters at admission
TnT 0.03 ng/ml 27 (3.01)
Copeptin (pmol/l) 5.4 (2.9/11.9)
Myoglobin (ng/ml) 58.8 (43.13/82.85) 6
CK-MB (U/l) 14 (11/18)
NT-proBNP (pg/ml) 119 (47.2/345) 20
C-reactive protein (mg/l) 2.3 (1.1/5.5)
Creatinine (mg/dl) 0.93 (0.8/1.07) 0
eGFR (ml/min for 1.73 m2) 81.2 21.5
Time of chest pain onset, h
3 332 (36.8)
6 520 (57.6)
12 666 (73.8)
12 237 (26.2)
ata presented as n (%) of patients, mean  SD for even variables, or median and 25th/75th int
ndex: 1,297; waist-hip ratio: 879; hypertension: 1,385; diabetes mellitus: 1,372; smoking status
LDL) cholesterol: 1,223; parental coronary artery disease (CAD): 1,328; troponin T (TnT): 1,378; c
,350; N-terminal pro-brain natriuretic peptide (NT-proBNP): 543; estimated glomerular filtration rate (eG
AMI  acute myocardial infarction; NCCP  noncoronary chest pain; UAP  unstable angina pectoris.o 50 ng/ml, 99th percentile was 0.04 ng/ml, and 10% CV
as 0.03 ng/ml.
Copeptin was measured in ethylenediaminetetraacetic
cid plasma by sandwich immunoluminometric assay (CT-
roAVP LIA B.R.A.H.M.S AG, Hennigsdorf, Germany)
s described in detail elsewhere (17,20). The assay has an
nalytical detection limit of 0.4 pmol/l and a functional
ssay sensitivity (lowest value with an interassay CV 20%)
1.0 pmol/l and allows precise measurement of copeptin in
range of 0.4 to 1,250 pmol/l.
To determine a diagnostic cutoff based on a reference
opulation, copeptin was measured with the same assay as
escribed in the preceding text in 5,000 individuals of the
utenberg Heart Study. Characteristics of the participants
re given in Online Table 1. On the basis of the distribution
f copeptin, different potential cutoff values were considered
Fig. 1): the 99th percentile with 18.9 pmol/l as suggested
AP AMI All
3.3) 299 (21.6) 1,386 (100)
 10.2 64.2 11.3 61.5 13.4
6.3) 229 (76.6) 920 (66.4)
 4.5 28.3 4.8 27.9 4.9
.94/1.04) 1.02 (0.96/1.05) 0.99 (0.94/1.04)
7.5) 224 (74.9) 1,025 (74)
6.2) 67 (22.6) 250 (18.2)
7.1) 99 (33.7) 322 (23.5)
7.9) 93 (35.4) 420 (32.9)
7.2) 96 (33.3) 616 (45.6)
2.1) 225 (75.3) 1,000 (72.2)
 47.5 202.7 49.5 195.9 46.5
 14.7 48.2 14.1 51.4 15.8
 42.4 125.8 43.7 116.2 40.8
.5/3.1) 2.7 (2/3.5) 2.3 (1.6/3)
5.1) 95 (33.5) 456 (34.3)
2) 103 (35.4) 499 (37.2)
.19) 184 (61.95) 215 (15.6)
/11.9) 18.5 (7/50.1) 6.7 (3.3/16.5)
6.5/82.6) 128.5 (83.89/238.92) 67.55 (46.88/102.58)
1/18) 21 (15/32) 15 (12/20)
3.2/566.6) 442.5 (141.5/1,277.1) 161 (64.3/572.5)
.3/4.5) 3.7 (1.8/10) 2.5 (1.3/6)
.81/1.04) 0.98 (0.88/1.16) 0.94 (0.82/1.08)
 21.2 76.1 22.6 79.9 21.8
4.8) 121 (40.5) 517 (37.3)
0.3) 175 (58.5) 806 (58.2)
5.5) 212 (70.9) 1,017 (73.4)
4.5) 87 (29.1) 369 (26.6)
ile range for skewed variables. Number of patients for which data were available for: body mass
; hyperlipidemia: 1,386; high-density lipoprotein (HDL) cholesterol: 1,223; low-density lipoprotein
n: 1,382; C-reactive protein: 1,377; myoglobin: 1,216; creatine kinase-myocardial band (CK-MB):Pain
U
184 (1
65.5
122 (6
28.2
.98 (0
161 (8
48 (2
31 (1
64 (3
83 (4
151 (8
193.5
50.3
113.4
2.2 (1
59 (3
111 (6
4 (2
5.1 (3
5.9 (4
14 (1
5.5 (8
2.3 (1
.92 (0
80
64 (3
111 (6
139 (7
45 (2
erquart
: 1,273
opeptiFR): 1,383; creatinine: 1,383; and time of chest pain onset: 1,386.
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May 11, 2010:2096–106 Copeptin in Diagnosis of Myocardial Infarctionor a biomarker in diagnosis of an AMI by the universal
efinition, the 97.5th percentile with 13 pmol/l as 95% of the
easured values define the reference range of a biomarker, and
he 95th percentile with 9.8 pmol/l as copeptin showed a
kewed distribution and as only the upper reference limit is of
nterest in this context. Technical assistants measuring copep-
in were blinded to the patients’ characteristics.
To estimate glomerular filtration rate, the abbreviated Mod-
fication of Diet in Renal Disease equation was used (21).
tatistical analysis. Skewed variables were described by
edian and interquartile range. Symmetric variables were
haracterized by arithmetic mean and SD.
Association between copeptin and different continuous
ariables was assessed with Spearman rank correlation
oefficient. The Mann-Whitney test was used to compare
he median levels of copeptin among different groups
efined by binary risk factors.
To describe changes over time, the Page L test for
rdered alternatives was used in markers with continuous
ncrease or decrease, and the Friedman 2-way analysis of
ariance by ranks test was used in markers without an
bvious trend (22).
Receiver-operating characteristic (ROC) curves based on
ontinuously measured biomarker levels dependent on time
ince chest-pain onset were calculated and graphed by using
ogistic regression according to diagnosis; all biomarkers
ntered these analyses after being log-transformed, due to
heir skewness. A nonparametric approach according to
eLong et al. (23) was used to test for difference between
he areas under the curve (AUCs). Confidence intervals for
he AUCs were constructed with the covariance matrix
stimated by the DeLong et al. method.
Additionally, positive predictive values (PPVs), negative
Figure 1 Histogram of Copeptin in the General Population
Distribution of copeptin values in 5,000 representative individuals of the Gutenberredictive values (NPVs), sensitivity, and specificity for the aarget markers were assessed by first applying a marker-
pecific cutoff value and consecutively calculating the corre-
ponding values from a 2  2 table in the usual way that
hese quantities are defined. Because these numbers repre-
ent proportions, 95% confidence limits for binomial dis-
ributed variables are given additionally. All analyses were
one with R 2.9.0 (R Foundation for Statistical Computing,
ienna, Austria).
esults
aseline characteristics. Table 1 provides the baseline
haracteristics of the overall study population at admission.
ean age was 61.5 years; 33.6% of the patients presented
ere women. In 903 of the 1,386 enrolled patients, an ACS
ould be excluded; these patients were classified as having
CCP, including patients with diagnosis of decompensated
ortic valve stenosis (n  2), aortic dissection (n  5),
yocarditis (n 13), decompensated heart failure (n 16),
nd pulmonary embolism (n  17).
Discharge diagnosis of AMI was made in 299 patients
21.6%), including 93 patients (6.7%) having an ST-
egment elevation MI. The diagnosis of UAP was made in
84 (13.3%) patients. The observed distribution of approx-
mately 22% AMI and 35% ACS is in line with other
uropean studies (24). Traditional risk factors were more
ommon in ACS patients. As anticipated, biomarkers of
yocardial necrosis as well as copeptin levels were highest in
atients suffering AMI. The distribution of CPO time was
omparable amongst all groups categorized according to
iagnosis.
nalyses of serial blood sampling. In addition to blood
ampling at admission, serial samples were obtained after 3
rt Study with corresponding 95th, 97.5th, and 99th percentiles.g Heand 6 h. To prospectively assess the time course of the
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Copeptin in Diagnosis of Myocardial Infarction May 11, 2010:2096–106valuated potential early biomarkers, patients with discharge
iagnosis of AMI (n  75) or NCCP (n  213) presenting
ith CPO 2 h were selected. Figure 2 illustrates the
epresentative time courses of TnT, copeptin, myoglobin,
nd CK-MB in those patients during the first 6 h after
dmission. Median troponin T levels strongly increased
ithin 6 h after admission (p  0.001). By contrast,
opeptin levels decreased during the first 6 h from its peak
t admission (p  0.001). Levels of myoglobin seemed to
ncrease during the first 3 h and decline afterward (p 
.397), whereas CK-MB concentration continuously in-
reased within the observed 6 h (p  0.001).
iomarker concentration according to CPO. Table 2
utlines the course of biomarker concentration at admission
ccording to CPO time in the overall study population. The
oncentration of TnT continuously increased with CPO
ime in AMI patients, reaching a maximum later than 12 h
fter CPO. In AMI patients with CPO of3 h, mean TnT
as at the concentration of 10% CV with 0.03 ng/ml.
In contrast, median copeptin levels were highest in AMI
atients with CPO below 3 h. In this time interval, patients
ith AMI had 5-fold higher copeptin levels (29.6 pmol/l)
ompared with NCCP (5.7 pmol/l) and UAP (5.45 pmol/l)
Figure 2 Representative Time Course of Copeptin, Troponin T,
Patients Suffering AMI on the Basis of Serial Samplin
Data selected for patients with final diagnosis of acute myocardial infarction (AMI)
NCCP n  213). Levels of copeptin, troponin T, myoglobin, and creatine kinase-my
3 and 6 h after admission. Data represent median concentrations with 95% bootsatients. Median copeptin levels decreased over time, reach-
ng values comparable to NCCP and UAP in patients
resenting later than 12 h after CPO.
In patients with CPO below 3 h, NT-proBNP levels
ere elevated 2.5-fold in AMI patients compared with
CCP, increasing within 12 h after CPO. As expected, in
MI patients, myoglobin was already elevated 2-fold in
atients presenting earlier than 3 h, peaking within 12 h
fter CPO. The time course of CK-MB showed a slower
ncrease and later peak.
orrelates of copeptin. Association between classical risk
actors and median copeptin levels according to diagnosis is
isplayed in Table 3. Men, obese patients, smokers, and
atients with diabetes in the NCCP group and patients with
iabetes in the UAP group had significantly higher copeptin
evels. Female patients presenting with AMI had lower
opeptin levels compared with male patients (13.55 pmol/l
s. 18.6 pmol/l; p  0.25); this might be explained by the
onger time interval between CPO and admission of female
atients. Furthermore, prevalence of hypertension and hy-
erlipidemia tended to be related to copeptin levels.
Table 3 also shows the correlation of continuous risk
ariables and of serum biomarkers and copeptin. Myoglobin
lobin, and CK-MB Levels in
ing First 6 h After Admission
coronary chest pain (NCCP) with time of chest pain onset 2 h (AMI n  75,
ial band (CK-MB) were measured in blood samples drawn at admission (0 h) and
nfidence interval.Myog
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or non
ocard
trap co
a
c
p
t
c
D
n
c
c
a
s
h
p
C
A
m
p
i
g
p
T
c
t
0
h
p
w
m
a
N
t
n
t
s
a
m
(

8
b
h
N
d
c
N
9
H
(
p
e
a
0
2101JACC Vol. 55, No. 19, 2010 Keller et al.
May 11, 2010:2096–106 Copeptin in Diagnosis of Myocardial Infarctions a marker of necrosis showed a mild correlation to
opeptin in all diagnosis groups, TnT in NCCP and AMI
atients, whereas CK-MB had no correlation with copep-
in. Furthermore, creatinine and eGFR, showed a signifi-
ant correlation with copeptin in all diagnostic groups.
iagnostic value of copeptin. To compare the discrimi-
atory ability of the continuous biomarkers troponin T,
opeptin, myoglobin, and CK-MB in detecting MI, ROC
urve analysis with AUC determination was performed
ccording to different times after CPO (Table 4, upper
ection). The AUC for TnT increased over time, with
ighest value in the overall population (0.84) compared with
atients presenting as early as 12, 6, and 3 h after CPO.
K-MB showed dynamics similar to troponin T with lower
UCs in all groups. In contrast, copeptin as well as
yoglobin provided the highest discriminatory power in
atients with CPO 3 h.
Adding the markers copeptin, myoglobin, and CK-MB
ndividually to TnT improved the AUC significantly in all
roups in comparison with troponin T alone. In patients
resenting within 3 h after CPO, addition of copeptin to
nT revealed highest diagnostic power with AUC of 0.9
ompared with addition of myoglobin to TnT. Combina-
ion of copeptin and TnT stayed superior with AUCs of
.91, 0.92, and 0.93 in patients with CPO of6 h and12
, and the overall population, respectively. Considering all
atients at baseline, the combination of copeptin and TnT
as superior to all single marker determinations or other
Levels of Copeptin, TnT, Myoglobin, CK-MB, andAccording to Time of Chest Pain Onset and Fi aTable 2 L vels f opeptin, T T, Myoglobi ,According to Time of Chest Pain On
0–3 h 3–6
TnT (ng/ml)
NCCP 0.01 (0.01/0.01) 0.01 (0.01/0.
UAP 0.01 (0.01/0.01) 0.01 (0.01/0.
AMI 0.03 (0.01/0.1) 0.06 (0.02/0.
Copeptin (pmol/l)
NCCP 5.7 (3.1/13.07) 5.1 (2.62/13
UAP 5.45 (3.54/14.56) 3.9 (2.7/9.6
AMI 29.6 (9.83/69.37) 25.5 (9.17/61
Myoglobin (ng/ml)
NCCP 55.9 (41.38/80.96) 59.1 (44.57/8
UAP 65.7 (43.12/81.56) 66.2 (49.8/77
AMI 144 (84.66/241.33) 131 (79.93/3
CK-MB (U/l)
NCCP 14 (11/18) 14 (11.92/1
UAP 12 (10/17.08) 17 (12/23.0
AMI 18 (14/24) 22 (16/29)
NT-proBNP (pg/ml)
NCCP 84.5 (40.92/222.33) 131 (55.67/5
UAP 140 (57.42/372.58) 201 (122.5/3
AMI 211 (89.83/721.83) 506 (122.33/
Data presented as median and 25th/75th interquartile range of conc
admission according to chest pain onset time.
Abbreviations as in Table 1.arker combinations. cUsing NT-proBNP as a diagnostic biomarker resulted in
n AUC of 0.7 in the overall population; the combination of
T-proBNP and TnT was not significantly superior to
roponin alone (AUC 0.87 vs. 0.84; p  0.145).
The ROC curves of the single markers and their combi-
ation in serial samples at admission and after 3 and 6 h in
he overall study population are graphed in Figure 3.
The lower section of Table 4 shows sensitivities and
pecificities as well as PPV and NPV for TnT, copeptin,
nd myoglobin and combinations of these biomarkers for
easured values above the respective cutoff.
TnT showed a high specificity, independent of CPO
97.9%, 97.7%, and 97.7% with CPO 3 h, 6 h, and
12 h, respectively), as well as the highest PPV (88.1%,
7.9%, and 88.2%) compared with copeptin and myoglo-
in. The combination of TnT and myoglobin showed
igher sensitivity (75.9%, 77.6%, and 77.6%) and higher
PV (89.9%, 91.1%, and 91.6%) than TnT alone with
ownside of lower specificity and PPV. Combining
opeptin and TnT resulted in even higher sensitivity, and
PV with all 3 used cutoff values representing the 95th,
7.5th, and 99th percentiles of a general population.
ighest sensitivity (85.1%, 87.4%, and 88.2%) and NPV
92.4%, 93.9%, and 94.6%) were achieved with 9.8
mol/l as the cutoff representing the 95th percentile.
If patients with ST-segment elevation (n  93) were
xcluded from the AMI group, single TnT determination at
dmission in the overall population showed an AUC of
.87, which improved to 0.93 (p  0.001) by adding
roBNPgnosisB, and NT-proBNP
nd Final Diagnosis
6–12 h >12 h
0.01 (0.01/0.01) 0.01 (0.01/0.01)
0.01 (0.01/0.01) 0.01 (0.01/0.01)
0.06 (0.01/0.32) 0.28 (0.08/0.8)
5.15 (2.8/11.31) 5.4 (2.97/10)
4.65 (2.23/15.17) 6.4 (3.57/10.77)
18.6 (7.77/33.17) 8.4 (4.13/17.3)
62 (46.92/82.23) 60.7 (44.12/81.48)
69 (37.13/106.25) 61.7 (49.82/83.95)
117 (84.35/320.5) 125 (82.13/181.67)
14 (11/17) 15 (11/19.08)
15 (11.17/18) 14 (12/17.33)
24 (16/44.67) 28 (16/66.17)
) 135 (54.67/673.67) 139 (66/489.83)
) 166 (70.67/540.25) 281 (136.33/1,006.67)
.58) 606.5 (212.42/960.58) 604 (341.17/2,032)
ns of TnT, copeptin, myoglobin, CK-MB, and NT-proBNP assessed atNT-pl DiaCK M
set a
h
01)
01)
2)
.1)
7)
.89)
8.77)
.47)
78.5)
8.08)
8)
74.33
54.33
1,879
entratioopeptin. In patients with CPO 3 h, the AUC for TnT
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Copeptin in Diagnosis of Myocardial Infarction May 11, 2010:2096–106lone was 0.79; for the combination of troponin and
opeptin, the AUC improved to 0.9 (p 0.001). Sensitivity
nd NPV of TnT alone with 10% CV as cutoff was 64.7%
nd 92.4%, respectively, in the overall population and 46.7%
nd 89.0% in patients with CPO 3 h. Applying the 95th
ercentile cutoff of 9.8 pmol/l for copeptin in combination
ith TnT improved sensitivity and NPV to 89.3% and
6.5%, respectively, in the overall population and to 81.3%
nd 94.0% in patients with CPO 3 h.
Regarding rule-out of ACS including AMI and UAP, de-
ermination of TnT at admission with 10% CV as cutoff pro-
ided an NPV of 74.9%; in combination with copeptin with
he 95th percentile as cutoff, an NPV of 80% was achieved. In
atients with CPO 3 h, the NPV increased from 70.8% for
nT alone to 77.8% in combination with copeptin.
arly evaluation of AMI with a more sensitive troponin.
dditional to conventional TnT, data are given in Table 5
Median Concentration of Copeptin According toand Correlatio With C ntinuous Variables AccTable 3 Medi n Conce tratio of Copeptin Aand Correlation With Continuous Va
NCCP (n  899)
Copeptin p Value
Male 6.7 0.001
Female 3.55
Body mass index (kg/m2)
30 6.45 0.0048
30 4.8
Hypertension
Yes 5.7 0.08
No 4.85
Diabetes mellitus
Yes 7.5 0.001
No 5.2
Current smoking
Yes 4.7 0.018
No 5.6
Hyperlipidemia
Yes 5.25 0.15
No 5.9
Known CAD
Yes 5.6 0.56
No 5.3
NCCP
r p Value
Age 0.2 0.001
LDL/HDL ratio 0.03 0.45
Waist/hip ratio 0.16 0.001
Creatinine 0.35 0.001
eGFR 0.22 0.001
C-reactive protein 0.2 0.001
TnT 0.19 0.001
Myoglobin 0.26 0.001
CK-MB 0.04 0.27
NT-proBNP 0.11 0.052
Correlations with continuous variables are given as Spearman correla
Abbreviations as in Table 1.n a more sensitive troponin I representative for a new beneration of commercially available troponin assays with
0% CV below the 99th percentile as recommended by the
niversal definition of MI. In identification of AMI patients
resenting within 3 h after CPO, troponin I delivered an
UC of 0.96 (0.95 to 0.98); the combination with copeptin
mproved the AUC slightly to 0.97 (0.96 to 0.98) (p 
.0397). Application of the 99th percentile cutoff of 0.04
g/ml showed a high sensitivity of 86.7% and NPV of 95%;
he combination with copeptin with the 95th percentile of
.8 pmol/l was able to improve the sensitivity to 98.3% and
PV to 99%. The combination had a sensitivity of 79.3%
nd an NPV of 84.6%, in exclusion of an ACS.
iscussion
arly identification of patients at risk in a population with
ndifferentiated chest pain is essential, because these patients
gorical Risk Factorst Diagnosisrding to Categorical Risk Factors
es According to Diagnosis
UAP (n  184) AMI (n  299)
Copeptin p Value Copeptin p Value
6.15 0.058 18.6 0.25
4.2 13.55
7.2 0.062 13.6 0.22
4.35 20.9
5.4 0.38 19.6 0.58
4.5 13.9
8 0.045 21.8 0.11
4.6 15.1
7.8 0.82 17.3 0.66
4.85 18.5
5.4 0.76 15.6 0.016
4.8 24.6
5 0.58 17.3 0.94
5.1 20.2
UAP AMI
r p Value r p Value
.17 0.021 0.12 0.038
.09 0.27 0.09 0.14
.02 0.83 0.13 0.086
.4 0.001 0.2 0.001
.32 0.001 0.19 0.0010
.17 0.02 0.18 0.0022
.11 0.15 0.28 0.001
.23 0.0051 0.24 0.001
.09 0.26 0.01 0.88
.12 0.24 0.21 0.021
fficients.Caterdingcco
riabl
0
0
0
0
0
0
0
0
0
0enefit the most from an aggressive therapeutic regimen.
AUC, Sensitivity, Specificity, PPVs, and NPVs for NCCP Versus AMI for TnT,Copeptin, Myoglobin, CK-MB, and Combination According to Time of Chest Pain OnsetTable 4 AUC, Sensitivity Specificity, PVs, and N Vs f r NCCP Versus AMI for TnT,Copeptin, Myoglobin, CK-MB, and Combination According to Time of Chest Pain Onset
<3 h <6 h <12 h All
AUC (CI) p Value vs. TnT AUC (CI) p Value vs. TnT AUC (CI) p Value vs. TnT AUC (CI) p Value vs. TnT
Troponin T 0.77 (0.72–0.82) 0.8 (0.76–0.84) 0.81 (0.77–0.84) 0.84 (0.82–0.87)
Copeptin 0.79 (0.75–0.84) 0.504 0.78 (0.75–0.82) 0.597 0.78 (0.74–0.81) 0.217 0.74 (0.7–0.77) 0.001
Myoglobin 0.83 (0.78–0.88) 0.0140 0.83 (0.79–0.86) 0.112 0.82 (0.78–0.86) 0.341 0.82 (0.79–0.85) 0.331
CK-MB 0.68 (0.63–0.74) 0.0140 0.7 (0.66–0.75) 0.001 0.72 (0.68–0.76) 0.001 0.73 (0.7–0.77) 0.001
Combination TnT/Cop 0.9 (0.88–0.93) 0.001 0.91 (0.89–0.93) 0.001 0.92 (0.9–0.94) 0.001 0.93 (0.92–0.95) 0.001
Combination TnT/Myo 0.89 (0.85–0.92) 0.001 0.89 (0.86–0.92) 0.001 0.89 (0.86–0.92) 0.001 0.91 (0.89–0.93) 0.001
Combination TnT/CK-MB 0.83 (0.78–0.88) 0.001 0.85 (0.81–0.89) 0.001 0.85 (0.82–0.89) 0.001 0.88 (0.85–0.9) 0.001
TnT* Myoglobin* Copeptin* Copeptin*† Copeptin*‡
TnT* or
Myoglobin*
TnT* or
Copeptin*
TnT* or
Copeptin*†
TnT* or
Copeptin*‡
3 h
Sensitivity 43 (34–52.3) 62.3 (52.3–71.5) 75.2 (66.5–82.6) 70.2 (61.3–78.2) 63.6 (54.4–72.2) 75.9 (67–83.3) 85.1 (77.5–90.9) 82.6 (74.7–88.9) 80.2 (71.9–86.9)
Specificity 97.9 (95.7–99.1) 87.5 (83.1–91.1) 68.1 (62.7–73.1) 75.1 (70–79.7) 83.3 (78.8–87.2) 85.9 (81.3–89.7) 66.7 (61.3–71.8) 73.4 (68.3–78.1) 81.7 (77–85.7)
PPV 88.1 (77.1–95.1) 64.7 (54.6–73.9) 46.4 (39.3–53.7) 50.9 (43.1–58.7) 58.3 (49.4–66.8) 68.2 (59.4–76.1) 48.6 (41.7–55.5) 53.5 (46.1–60.8) 61.8 (53.7–69.4)
NPV 82.4 (78.3–86) 86.3 (81.8–90) 88.2 (83.6–91.9) 87.3 (82.8–90.9) 86.2 (81.9–89.8) 89.9 (85.7–93.2) 92.4 (88.2–95.4) 92 (88–95) 91.8 (88–94.6)
6 h
Sensitivity 50 (42.3–57.7) 61.4 (53.2–69.2) 74.9 (67.8–81.1) 69.1 (61.7–75.9) 63.4 (55.8–70.6) 77.6 (70.6–83.7) 87.4 (81.6–92) 84 (77.7–89.1) 81.1 (74.5–86.6)
Specificity 97.7 (96–98.8) 85.8 (82.2–88.8) 67.6 (63.4–71.7) 74.8 (70.8–78.5) 82 (78.4–85.2) 83.9 (80.3–87.2) 66.2 (61.9–70.3) 73.2 (69.2–77) 80.3 (76.6–83.6)
PPV 87.9 (79.8–93.6) 59.1 (51.1–66.8) 44 (38.2–49.8) 48.2 (41.9–54.6) 54.4 (47.3–61.4) 64.1 (57.1–70.6) 46.9 (41.4–52.5) 51.8 (45.8–57.7) 58.4 (52–64.7)
NPV 85.3 (82.2–88) 86.9 (83.5–89.9) 88.8 (85.3–91.7) 87.7 (84.3–90.6) 86.9 (83.5–89.7) 91.1 (87.9–93.6) 93.9 (90.9–96.1) 93.1 (90.1–95.3) 92.6 (89.7–94.8)
12 h
Sensitivity 53.1 (46.1–60) 60.1 (52.6–67.3) 74.1 (67.6–79.8) 67.5 (60.7–73.7) 60.8 (53.9–67.5) 77.6 (71.2–83.1) 88.2 (83.1–92.2) 84.9 (79.4–89.4) 82.1 (76.2–87)
Specificity 97.7 (96.3–98.7) 86.2 (83.2–88.9) 68 (64.3–71.5) 75.8 (72.4–79) 82.5 (79.4–85.3) 84.5 (81.3–87.3) 66.9 (63.1–70.5) 74.6 (71.1–77.9) 81.2 (78–84.1)
PPV 88.2 (81.3–93.2) 57.6 (50.2–64.7) 42.5 (37.4–47.8) 47.2 (41.5–53) 52.7 (46.2–59) 63.3 (57.1–69.3) 46.2 (41.2–51.2) 51.9 (46.5–57.2) 58.4 (52.6–64)
NPV 86.7 (84.1–89.1) 87.4 (84.4–90) 89.1 (86.1–91.7) 87.9 (85–90.5) 86.8 (83.9–89.4) 91.6 (89–93.8) 94.6 (92.2–96.5) 93.9 (91.5–95.8) 93.4 (91–95.3)
All
Sensitivity 62 (56.2–67.5) 61 (54.8–66.9) 65.6 (59.9–70.9) 57.5 (51.7–63.2) 49.2 (43.4–55) 81 (76–85.4) 90.9 (87.1–93.9) 87.6 (83.3–91.1) 84.6 (80–88.5)
Specificity 97 (95.7–98) 86.6 (84–88.9) 69.7 (66.6–72.7) 77.9 (75–80.5) 84.4 (81.9–86.7) 84.5 (81.8–86.9) 68.3 (65.1–71.3) 76.2 (73.2–78.9) 82.4 (79.8–84.9)
PPV 87.2 (81.9–91.4) 60.1 (53.9–66) 41.9 (37.4–46.5) 46.4 (41.2–51.6) 51.2 (45.3–57.1) 65.3 (60.1–70.2) 48.8 (44.6–53.1) 55.1 (50.5–59.6) 61.6 (56.7–66.4)
NPV 88.5 (86.4–90.4) 87 (84.5–89.3) 85.9 (83.2–88.3) 84.6 (82–87) 83.3 (80.7–85.7) 92.5 (90.4–94.3) 95.8 (93.9–97.2) 94.8 (93–96.3) 94.1 (92.2–95.7)
AUC, sensitivity, specificity, PPVs, and NPVs for NCCP versus AMI for troponin T, copeptin, myoglobin, CK-MB, and the combination of troponin T with each other marker according to time of chest pain onset. The AUC, sensitivity, specificity, and negative (NPV) and positive
predictive value (PPV) are given with corresponding 95% confidence interval (CI). Chest pain onset was 3 h in 517 patients, 6 h in 806 patients, 12 h in 1,017 patients, and 12 h in 369 patients. *Concentrations greater than cutoff. Cutoffs: troponin T 0.03 ng/ml;
myoglobin 107 ng/ml; copeptin (95th percentile) 9.8 pmol/l; †copeptin (97.5th percentile) 13 pmol/l; ‡copeptin (99th percentile) 18.9 pmol/l.
Cop  copeptin; Myo  myoglobin; TnT  troponin T; other abbreviations as in Table 1.
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Copeptin in Diagnosis of Myocardial Infarction May 11, 2010:2096–106Cardiac TnT, the basis of the diagnostic work-up, had a
ow sensitivity of 43% in detecting AMI in patients pre-
enting within 3 h. In this important group, copeptin had a
ensitivity of 75.2%, being more sensitive than TnT as well
s myoglobin (62.3%). The overall diagnostic performance
f a single copeptin measurement reflected by ROC analysis
ould only challenge TnT within the first 6 h, due to lower
pecificity. Therefore, copeptin is not able to replace tropo-
in in final rule-in of AMI but allows earlier decision-
aking in clinical practice.
Combination of cardiac troponin with markers of differ-
nt origin or variant release kinetics should, in theory, add
iagnostic information. Indeed, we showed that combining
nT and copeptin, which reflects a physiologic hemody-
amic stress response to myocardial ischemia, significantly
mproved the ROC performance within 3 h after CPO.
yoglobin as a marker of myocardial necrosis added less to
nT compared with copeptin. The approach of adding
Figure 3 Diagnostic Power of Copeptin, Troponin, and Classica
Receiver operating characteristic curves and corresponding area under the curve f
creatine kinase-myocardial band (CK-MB), and their combination for serial samples
Sensitivity, Specificity, PPVs, and NPVs for NCMore Sensitive TnI and Copepti in atients PChe t Pain Onset
Table 5
nsitivity, Specificity, PVs, and
More Sensitive TnI and Copeptin
Chest Pain Onset
Sensitive TnI*
Sensitiv
Cope
AMI
Sensitivity 86.7 (79.3–92.2) 98.3 (94
Specificity 92.4 (89.1–95.1) 63.2 (57
PPV 80.6 (72.7–87) 49.4 (42
NPV 95.0 (92.1–97.1) 99.0 (96
ACS
Sensitivity 62.5 (55.1–69.5) 79.3 (72
Specificity 92.4 (89.1–95.1) 63.2 (57
PPV 82.1 (74.8–88.1) 54.7 (48
NPV 81.6 (77.3–85.4) 84.6 (79
Sensitivity, specificity, NPV, and PPV are given with corresponding 95%
included. *Concentrations greater than cutoff. Cutoffs: troponin I (Tn
percentile) 13 pmol/l; ‡copeptin (99th percentile) 18.9 pmol/l.
Abbreviations as in Tables 1 and 4.opeptin to TnT provided stable diagnostic performance
lbeit time of presentation after CPO, which reflects both
he early peak of copeptin with the following decrease and
he slow increase of TnT levels over time.
The observed high sensitivity in the first hours after CPO
akes copeptin an ideal candidate to complement troponin
ith its high specificity to accurately rule out AMI at
dmission. Our study supports this assumption, with an
PV of copeptin using the 95th percentile as cutoff com-
ined with TnT using the 10% CV as cutoff of nearly 96%
n the overall population and of already 92.4% in patients
resenting within 3 h after CPO.
Regarding myoglobin, an established early marker of
yocyte necrosis, our results are in line with previous
tudies (25). In the overall picture, we could show a clear
uperiority of copeptin over myoglobin in our setting.
Disease entities of nonischemic etiology like myocarditis
lso might lead to elevated troponin levels and, therefore,
rosis Markers
onin T (TnT), copeptin (Cop), myoglobin (Myo),
mission and after 3 and 6 h for the overall study population.
Versus AMI and ACS for anting Within 3 h Afters for NCCP Versus AMI and ACS for a
tients Presenting Within 3 h After
or Sensitive TnI or
Copeptin*†
Sensitive TnI or
Copeptin*‡
.8) 96.7 (91.7–99.1) 96.7 (91.7–99.1)
.4) 69.3 (64–74.2) 76.9 (72–81.3)
.9) 53.5 (46.6–60.2) 60.4 (53.1–67.4)
.9) 98.3 (95.6–99.5) 98.4 (96.1–99.6)
) 77.2 (70.4–83) 73.4 (66.4–79.6)
.4) 69.3 (64–74.2) 76.9 (72–81.3)
.8) 58.4 (52–64.7) 64 (57.1–70.5)
.8) 84.4 (79.6–88.6) 83.8 (79.1–87.7)
ence interval. A total of 517 patients with chest pain onset3 h were
4 ng/ml; copeptin (95th percentile) 9.8 pmol/l; †copeptin (97.5thl Nec
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at adCPreseN V
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May 11, 2010:2096–106 Copeptin in Diagnosis of Myocardial Infarctionesult in lower specificity and PPV of troponin in evaluation
f chest pain patients. Serial troponin determination can
ossibly exclude chronic diseases like renal impairment
ccompanied by troponin elevation (26). To distinguish
ther entities with acute onset and troponin rise like aortic
issection (27), early biomarkers of different origin than
roponin like copeptin are amendatory, particularly in a real
orld population of patients with new-onset chest pain.
uch biomarkers could also be helpful, due to the slow
ecrease of troponin, in detection of re-infarction with
rolonged troponin elevation caused by initial necrosis.
In summary, we can state 3 major findings.
First, determination of copeptin as a single marker has
iagnostic value comparable to that of myoglobin, being
uperior to a conventional TnT within the first 3 h after
PO. Neither single copeptin nor myoglobin determination
s able, with regard to the overall population independent of
PO and need for high specificity, to displace or challenge
serial troponin T measurement to detect myocardial
ecrosis within a rule-in approach.
Second, combination of copeptin and TnT improves
iagnostic performance for detection of AMI compared
ith single TnT measurement on admission, being clearly
uperior in patients presenting within 3 h after CPO. In
ontrast, combination of myoglobin and TnT adds less
iagnostic information.
Third, combination of copeptin and conventional tropo-
in T aids in early rule-out of AMI virtually independent of
PO with high NPV in patients presenting as early as 0 to
h after CPO.
The current universal definition of MI (1) asks for use of
he 99th percentile as the troponin cutoff with CV of 10%
t this concentration. This demand stimulated development
f new troponin assays with high sensitivity in identification
f AMI within the first hours after CPO where established
roponins have shortcomings (2). Recently, we demon-
trated that a more sensitive troponin I representative for
his new troponin generation (28) provides a sensitivity of
4% in identification of AMI in patients presenting within
h after onset of chest pain (29). The present analysis shows
omparable sensitivity of 85.1% for the combination of
opeptin and conventional TnT in patients presenting as
arly as 3 h after CPO, compensating for the weakness of
stablished troponins in the early phase. Combination of
opeptin and more sensitive TnI could further improve
ensitivity to 98.3% in patients presenting within 3 h,
roviding an excellent NPV of 99% with the downside of
educed specificity and PPV.
Therefore, combination of copeptin and troponin is
seful in rapid evaluation of chest pain patients in many
ettings. Furthermore, in a point-of-care environment with
nherent lower test sensitivity of troponin, copeptin could
acilitate fast diagnosis and treatment initiation.
tudy limitations. Using conventional cardiac troponin as
diagnostic criterion might favor the tested troponinompared with copeptin and myoglobin. The percentage of
1atients with AMI was rather high in this all-comers study.
his distribution is in line with other European studies but
ight limit the use in populations with lower risk.
onclusions
n triage of patients with suspected ACS, combined assess-
ent of conventional troponin and copeptin improves
iagnostic performance, specifically in the first hours after
PO, and thus might accelerate therapeutic decision-
aking. The addition of the classical early marker myoglo-
in to conventional troponin had, compared with copeptin,
less ameliorative effect.
Combined determination of troponin and copeptin on
dmission in patients early after onset of chest pain provides
high NPV. This combination might aid in early and safe
ule-out of AMI and makes copeptin an ideal candidate to
omplement troponin in point-of-care testing.
eprint requests and correspondence: Dr. Stefan Blanken-
erg, Department of Medicine II, Johannes Gutenberg-
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